More evidence for use of pneumococcal conjugate vaccines

The Lancet

Volumn 381, Issue 9862, 2013, Pages 182-183

  Whitney, Cynthia G ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; DIPHTHERIA TOXOID; HEMOPHILUS INFLUENZAE PROTEIN D; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG;

CHILD HEALTH; DRUG EFFICACY; DRUG FORMULATION; FINLAND; HAEMOPHILUS INFLUENZAE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; NOTE; OBSERVATIONAL STUDY; OTITIS MEDIA; PNEUMOCOCCAL INFECTION; PNEUMONIA; PRIORITY JOURNAL; UNITED STATES; WORLD HEALTH ORGANIZATION;

EID: 84872586371     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61957-6     Document Type: Note

References (15)

1. Johns Hopkins Bloomberg School of Public Health International Vaccine Access Center (IVAC). VIMS Report: Global Vaccine Introduction, October 2012. http://www.jhsph.edu/research/centers-and-institutes/ivac/vims/ IVAC-VIMS-Report-2012-10.pdf (accessed Nov 2, 2012).
2. Palmu AA, Jokinen J, Borys D, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet 2012; published online Nov 16. http://dx.doi.org/10.1016/S0140-6736(12)61854-6.
3. Prymula R, Peeters P, Chrobok V, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006; 367: 740-48.
4. Tregnaghi MW, Sáez-Llorens X, López P, et al. Evaluating the efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine (PHiDCV) against community-acquired pneumonia in Latin America. ESPID 2011; June 7-11, 2011; The Hague, Netherlands, abstr 1411.
5. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19: 187-95.
6. O'Brien KL, Moulton LH, Reid R, et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 2003; 362: 355-61.
7. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344: 403-09.
8. Cutts FT, Zaman SM, Enwere G, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005; 365: 1139-46.
9. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003; 349: 1341-48.
10. World Health Organization. Pneumococcal conjugate vaccine for childhood immunization-WHO position paper. Wkly Epidemiol Rec 2007; 82: 93-104.
11. World Health Organization. Pneumococcal vaccines WHO position paper-2012. Wkly Epidemiol Rec 2012; 87: 129-44.
12. Scott P, Rutjes AW, Bermetz L, et al. Comparing pneumococcal conjugate vaccine schedules based on 3 and 2 primary doses: systematic review and meta-analysis. Vaccine 2011; 29: 9711-21.
13. Johnson HL, Deloria-Knoll M, Levine OS, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med 2010; 7: e1000348.
14. World Health Organization. Changing epidemiology of pneumococcal serotypes after introduction of conjugate vaccine: July 2010 report. Wkly Epidemiol Rec 2010; 85: 435-36.
15. World Health Organization. Meeting of the Strategic Advisory Group of Experts on Immunization, November 2011-conclusions and recommendations: review of serotype replacement in the setting of 7-valent pneumococcal conjugate vaccine (PCV-7) use and implications for the PCV10/PCV13 era. Wkly Epidemiol Rec 2012; 87: 12-13.